Teva Pharmaceuticals Launches Major Debt Refinancing Effort After Credit Rating Upgrade

Teva Pharmaceuticals is capitalizing on its recent upgrade to investment-grade credit rating by launching a significant debt refinancing initiative, aiming to raise over $4 billion in U.S. dollars and Euros. The company plans to use the proceeds, along with existing cash reserves, to replace higher-interest debt with new, lower-cost bonds. This strategic move comes shortly after S&P Global Ratings elevated Teva's credit rating to BBB-, rejoining Moody's and Fitch in assigning it an investment-grade status across all three major agencies.

This upgrade is crucial for Teva, which carries a substantial debt load of approximately $16.6 billion. An investment-grade rating typically lowers the perceived risk for investors, potentially expanding the pool of buyers for its bonds and reducing the cost of borrowing. Teva intends to redeem several existing bond series, including a $1.25 billion dollar bond maturing in 2028 with a 6.75% interest rate, a $400 million dollar bond due in 2029 at 7.875%, and a €660 million Euro bond at 7.375%. Additionally, the company plans to repurchase up to $450 million of a 2027 bond (4.75%) and up to €1.25 billion of a 2030 bond (4.375%), bringing the total debt targeted for refinancing to roughly $4.2 to $4.3 billion.

The refinancing aims to secure lower annual interest expenses and extend Teva's debt maturity profile. This proactive approach contrasts with its past struggles following the nearly $40 billion acquisition of Allergan's generics business in 2016, which ballooned its debt to nearly $36 billion. Over the years, Teva has successfully reduced its total debt by over $19 billion, bringing the net debt to around $13 billion by the end of June, with approximately $3.7 billion in cash.

Simultaneously, Teva is reinvesting in growth, evidenced by its recent $700 million cash acquisition of Imvexxy, a drug for Tourette syndrome. This strategic shift allows the company to pursue acquisitions while continuing to manage its leverage. Teva's financial health is further bolstered by strong second-quarter results, with revenues of about $4.1 billion, driven by significant growth in its key drugs like Austedo and Ajovy. The company anticipates free cash flow between $2 billion and $2.4 billion for the full year 2026.